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AbstrACt
Objectives To evaluate the cost-effectiveness of the 
implementation of the Identification and Referral to 
Improve Safety (IRIS) programme using up-to-date 
real-world information on costs and effectiveness from 
routine clinical practice. A Markov model was constructed 
to estimate mean costs and quality-adjusted life-years 
(QALYs) of IRIS versus usual care per woman registered 
at a general practice from a societal and health service 
perspective with a 10-year time horizon.
Design and setting Cost–utility analysis in UK general 
practices, including data from six sites which have been 
running IRIS for at least 2 years across England.
Participants Based on the Markov model, which uses 
health states to represent possible outcomes of the 
intervention, we stipulated a hypothetical cohort of 10 000 
women aged 16 years or older.
Interventions The IRIS trial was a randomised controlled 
trial that tested the effectiveness of a primary care 
training and support intervention to improve the response 
to women experiencing domestic violence and abuse, 
and found it to be cost-effective. As a result, the IRIS 
programme has been implemented across the UK, 
generating data on costs and effectiveness outside a trial 
context.
results The IRIS programme saved £14 per woman 
aged 16 years or older registered in general practice 
(95% uncertainty interval −£151 to £37) and produced 
QALY gains of 0.001 per woman (95% uncertainty interval 
−0.005 to 0.006). The incremental net monetary benefit 
was positive both from a societal and National Health 
Service perspective (£42 and £22, respectively) and the 
IRIS programme was cost-effective in 61% of simulations 
using real-life data when the cost-effectiveness threshold 
was £20 000 per QALY gained as advised by National 
Institute for Health and Care Excellence.
Conclusion The IRIS programme is likely to be cost-
effective and cost-saving from a societal perspective in the 
UK and cost-effective from a health service perspective, 
although there is considerable uncertainty surrounding 
these results, reflected in the large uncertainty intervals.
IntrODuCtIOn 
The lifetime prevalence of domestic violence 
and abuse (DVA) against women, including 
any form of controlling, coercive, threatening 
behaviour, violence and abuse, as well as 
non-physical forms of abuse as defined by the 
United Nations,1 varies internationally from 
15% to 71%.2 In the UK, in the year ending 
March 2017, 7.5% of women (1.2 million) 
experienced domestic abuse.3 Women who 
experience DVA suffer chronic health prob-
lems including gynaecological problems, 
gastrointestinal disorders, neurological symp-
toms, chronic pain, cardiovascular conditions 
and mental health problems.4–7 In 2012, the 
cost of DVA in the UK, including medical 
strengths and limitations of this study
 ► We have used up-to-date routine data from several 
sites across England to evaluate the value for mon-
ey of Identification and Referral to Improve Safety 
(IRIS), a domestic violence training programme.
 ► We were unable to include any impact of the IRIS 
programme on children exposed to domestic vio-
lence and abuse (DVA), as to our knowledge, there 
are no available cohort studies focusing on the cost 
and benefits of DVA interventions for this population.
 ► We have used mainly data on short-term outcomes, 
although modelled long-term outcomes, as to our 
knowledge, no study has tracked women subject to 
DVA over long periods of time.
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and social services, lost economic output and emotional 
costs, was estimated to be £11 billion.8 While such esti-
mates highlight the importance of DVA as a public health 
and clinical problem, information on cost-effectiveness is 
needed to make an economic case for investment in DVA 
interventions in healthcare, particularly when health 
systems are dominated by austerity.
The Identification and Referral to Improve 
Safety (IRIS)9 trial tested the effectiveness of a training 
and support intervention for general practice teams in 
two English cities.10 Discussions about DVA between 
clinicians and patients were 22 times greater in the inter-
vention practices compared with the control practices. 
Primary care practices that delivered the intervention 
also experienced a sixfold and threefold increase in refer-
rals received by DVA agencies and DVA-related notes 
in the patient medical records, respectively. The IRIS 
programme can now be commissioned across the UK: 
as of December 2016, 34 UK areas had commissioned 
IRIS, >800 general practitioner (GP) practices nationally 
have had IRIS training and over 5000 women have been 
referred to DVA support services by IRIS since 2010.
The cost-effectiveness of the IRIS trial was assessed using 
data from the trial and the programme was estimated to 
be good value for money.11 Given its national implemen-
tation, IRIS became a real-life, long-term intervention, 
raising the need for a new economic evaluation outside 
the trial context. The aim of this study was to evaluate 
the cost-effectiveness of the IRIS programme now that 
it has been implemented across the UK. Our estimates 
use up-to-date figures from an Medical Research Council 
(MRC) phase IV observational pragmatic implementation 
study12 on costs and effectiveness from routine clinical 
practice and the most up-to-date model input param-
eters, including a recently updated Cochrane review of 
domestic violence advocacy.13
MethODs
Overview of economic evaluation
This was a cost-utility analysis, comparing IRIS with usual 
care in general practices. The outcome measure was 
quality-adjusted life years (QALYs), as recommended 
for economic evaluations in the UK.14 The main analysis 
was from a societal perspective, as many of the costs of 
DVA are borne outside the health system; we also esti-
mated cost utility from a National Health Service (NHS) 
perspective. Costs were calculated in 2015/2016 UK£. We 
calculated costs and benefits over a 10-year time horizon, 
with future costs and outcomes discounted at an annual 
rate of 3.5%.14
Model structure
We developed a Markov model (figure 1) based on the 
previous analysis.11 The model has five states and the cycle 
length was 6 months; this length was chosen as it reflects 
the average amount of time women stay in contact with 
DVA advocacy services. We have used a half-cycle correc-
tion.15 A hypothetical cohort of 10 000 women aged 16 
years or older was simulated moving between the states 
Figure 1 Health states and movement between health states in Markov model. The model starts with all women in either the 
‘not abused’ state or one of the states associated with abuse, based on the prevalence of domestic violence and abuse (DVA) 
(see text). Women in the ‘not abused’ state could stay in this state, move to ‘abused but not identified’ or die from any cause. 
Once women were in the ‘abused but not unidentified’ state, they could stay in that state, move back to ‘not abused’, move 
to ‘abused and identified, seeing advocate’ or ‘abused and identified, not seeing advocate’ or die. Women in the ‘abused and 
identified’ states could stay in these states, move back to ‘not abused’ or die.
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(figure 1). Other than death, which is an absorbing state, 
women can transition between each of the other states 
'not abused', 'abused but not identified', 'abused and 
identified, seeing advocate educator', 'abuse and identi-
fied, not seeing advocate educator'. As the hypothetical 
cohort of women aged 16 years or older were considered 
eligible for the intervention, all results were reported 
as ‘per woman aged 16 years or older registered to GP 
practice’.
Intervention
The IRIS programme is a multicomponent intervention 
that has been described in detail elsewhere.10 11 In brief, it 
consists of two 2-hour multidisciplinary training sessions, 
for the practice clinical team and 1-hour training for 
reception and ancillary staff. They are delivered jointly 
by an IRIS advocate educator from a local collaborating 
specialist DVA agency, alongside a clinician interested 
in DVA, the IRIS clinical lead. The advocate educator 
is central to the intervention, combining a training and 
support role to the practices with provision of advocacy 
to women referred. Other intervention components 
include a simple 4-question questionnaire, carried out by 
the healthcare practitioner, addressing different aspects 
of DVA (humiliation, afraid, raped and kicked), such as 
"within the last year, have you been afraid of your partner 
of ex-partner?", also known as the HARK template16 in 
the electronic medical record triggered by entry of clin-
ical problem codes (such as depression, anxiety, irritable 
bowel syndrome, pelvic pain and assault), an explicit 
referral pathway to a named IRIS advocate educator 
and publicity materials about DVA visible in practices. 
Patients referred to the advocate educator are usually 
seen at the referring general practice, enhancing safety 
and confidentiality.
Data collection and ethics approval
Several different data sources were used in this study. 
Whenever possible, we have used observational data 
from the IRIS programme. These were collected by IRIS 
team members, liaising with advocacy agencies and local 
authorities. Given that we only use anonymised data, 
arising from the usual care of women, individual consent 
of women was not required. This research project was 
given exemption from NHS Research Ethics processes, as 
it was classified as service evaluation. When observational 
data were unavailable, we have chosen to use peer-re-
viewed published data that was relevant to general prac-
tice and the UK. Each relevant parameter and its source 
are described in detail below.
Prevalence of domestic abuse
The proportion of women aged 16 years or older experi-
encing abuse was estimated based on published epidemi-
ological data. This was taken from a cross-sectional study 
carried out by Richardson et al in east London,17 which 
reported a prevalence of 0.17 or 17% in the population 
of women consulting a GP or practice nurse. This is an 
estimate of the prevalence of DVA in general practice, 
generalisable for England.
transition probabilities
There are eight transitions between states in the model. 
Transition probabilities were obtained using observa-
tional data from the IRIS programme, the MOthers' 
Advocates In the Community programme,10 18 the Office 
for National Statistics19 20 and Health & Social Care Infor-
mation Centre21 and a Cochrane review,13 evaluating the 
reduction of any type of domestic abuse with any type of 
advocacy. Observational data were obtained from commis-
sioned IRIS sites that have been running for 2 years or 
more, where there was at least one full-time equivalent 
advocate educator and 20 general practices trained. It 
included six clinical commissioning groups in northern 
England, south-west England and London. Given the 
inclusion criteria, the sites represent the implementation 
of the programme. Table 1 provides the parameter values 
and their respective sources. Where no data were avail-
able, we have calculated estimates using the model cali-
bration method described below.
Model calibration
Because of uncertainty surrounding transition probabil-
ities from not abused to abused but not identified and vice 
versa, we used the prevalence of abuse (17%) estimated 
in the study by Richardson et al,17 to calibrate the model. 
The model was run for 3000 cycles, assuming that there-
after the number of women in each state would remain 
constant. This was based on our calculation of steady 
states. The transition probabilities from not abused to 
abused but not identified and vice versa were changed until 
the proportion of women in the not abused state exactly 
reflected the observed prevalence (100–17=83%). The 
initial distribution of women in the three abused states was 
also determined by this process.
utilities
Each state in the Markov model was associated with a 
utility score, which consisted of a general measure of 
health-related quality of life,22 allowing us to measure 
QALYs associated with IRIS and the comparator based 
on the proportion of women in each health state in each 
of the 20 six-monthly cycles in the model, totalling 10 
years. The utility score of women who were not abused 
was assumed to be 0.85.23 Wittenberg et al conducted a 
cross-sectional survey to estimate community preferences 
for health states resulting from intimate partner violence. 
Using a UK-based algorithm, they found the utility of 
women experiencing any abuse was 0.64. When the 
severity/frequency of violence was low, the mean utility 
was 0.65 and when the severity/frequency was moderate 
or severe the mean utility was 0.63. For women who were 
abused in our model, we assumed this was moderate to 
severe, giving a utility score of 0.63.24 For women seeing 
an advocate educator, we used the utility value of women 
with low abuse (0.65), implying that seeing an advocate 
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Table 1 Model input parameters: probabilities, utilities and costs
Parameter
Base 
case 
value
Lower 
limit
Upper 
limit Distribution Source
IRIS trial 
base 
value*
Probabilities
  Proportion of women experiencing abuse 0.17 0.147 0.194 Beta 17 0.17
  Starting distribution for women who are abused
   Abused and identified, seeing advocate 
educator
0.003† 0 0.0066 Uniform ‡ – 
   Abused and identified, not seeing advocate 
educator
0.033† 0 0.0660 Uniform ‡ – 
   Abused but not identified 0.964† – – Uniform Complement – 
  Transition probabilities
   Not abused to abused but not identified 0.0037† 0.0004 0.0106 Dirichlet ‡ 0.0075
   Not abused to dead 0.00551† 0.0010 0.0136 Dirichlet 13 15 0.0058
   Stay in Not abused 0.9908† - - Dirichlet Complement 0.9867
   Abused but not identified to not abused (control) 0.0500† 0.0450 0.0553 Dirichlet ‡ 0.025
   Abused but not identified to abused and 
identified, not seeing advocate educator 
(control)
0.0027† 0.0016 0.0040 Dirichlet IRIS-
programme 
local sites
0.0094
   Abused but not identified to abused and 
identified, seeing advocate educator (control)
0.0005† 0.0001 0.0011 Dirichlet IRIS-
programme 
local sites
0.0016
   Abused but not identified to dead (control) 0.00554† 0.0039 0.0074 Dirichlet 13 15 0.0059
   Stay in abused but not identified (control) 0.9444† - - Dirichlet Complement 0.9581
   Abused but not identified to not abused 
(intervention)
0.0500† 0.0450 0.0553 Dirichlet ‡ 0.025
   Abused but not identified to abused and 
identified, not seeing advocate educator 
(intervention)
0.0109† 0.0086 0.0135 Dirichlet IRIS-
programme 
local sites
0.0207
   Abused but not identified to abused and 
identified, seeing advocate educator 
(intervention)
0.0056† 0.0040 0.0076 Dirichlet IRIS-
programme 
local sites
0.0101
   Abused but not identified to dead (intervention) 0.00554† 0.0039 0.0074 Dirichlet 6 0.0059
   Stay in abused but not identified (intervention) 0.9419† - - Dirichlet Complement 0.9383
   Abused and identified, seeing advocate 
educator to not abused
0.1408† 0.0707 0.2301 Dirichlet 18 0.0888
   Abused and identified, seeing advocate 
educator to dead
0.00554† 0.0000 0.0309 Dirichlet 13 15 0.0059
   Stay in abused and identified, seeing advocate 
educator
0.8536† - - Dirichlet Complement 0.9053
   Abused and identified, not seeing advocate 
educator to not abused
0.0781† 0.0136 0.1912 Dirichlet 18 0.0717
   Abused and identified, not seeing advocate 
educator to dead
0.00554† 0.0000 0.0438 Dirichlet 13 15 0.0059
   Stay in abused and identified, not seeing 
advocate educator
0.9163† - - Dirichlet Complement 0.9223
Utilities
  Not abused 0.85 0.840 0.860 Beta 23 – 
  Abused but not identified 0.63 0.503 0.749 Beta 24 – 
  Abused and identified, seeing advocate educator 0.65 0.518 0.771 Beta 24 – 
Continued
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educator slightly increased their quality-of-life scores. 
QALY gains were reported per woman aged 16 years or 
older registered to GP practice.
Costs
We included intervention costs, costs of onward referral 
and costs associated with DVA (including costs to the 
UK NHS, lost economic output, costs to the criminal/
civil justice system and personal costs). Costs were also 
reported per woman aged 16 years or older registered to 
GP practice.
One IRIS advocate educator typically provides training, 
support and advocacy services for 24 general practices 
at any one point in time. Intervention costs were calcu-
lated based on the actual budget of the IRIS programme 
in the six sites (including advocate educator salaries, 
travel, recruitment, laptop, telephone, publicity, clinician 
consultancy, evaluation and central management costs) 
at a total 6-month cost across all sites of £272 613. This 
was divided by the number of registered women aged 
16+ years in IRIS-trained general practices in these sites 
(n=595 902). Costs of onward referral from the advocate 
educator was based on the finding of contact time from 
the IRIS trial, in which an onward referral was given to 
57% of women in contact with an advocate educator and 
63% of these women accepted this referral. Therefore, 
although costs of onward referral were based on current 
budgets and salaries, the proportion of contact was 
obtained from the trial estimates. Total costs per onward 
referral were therefore £861. Taking into account the 
proportion of women given a referral and accepting it, 
and inflating it to 2015/2016 UK£, average costs of advo-
cate educator contact per abused woman were £312.
Costs associated with intimate partner violence in the 
UK are described by Walby and Olive.8 In their report, 
costs of lost economic output, health services, criminal 
justice system, civil justice system, social welfare, personal 
costs, specialised services and physical/emotional 
impact were individually reported, and total costs were 
€13 732 million (£11 billion) in 2012. We excluded costs 
of physical/emotional impact (€6614 million), as they 
were not financial costs, but consisted of monetary valuing 
of health status, which in cost-effectiveness models ought 
to be captured in terms of QALYs; these were also not 
included in the original cost-effectiveness analysis. The 
remaining costs were converted to UK£ and inflated to 
2015/2016. Total costs per 6 months were £2933 million. 
Based on the 2015 Crime Survey for England and Wales, 
it was estimated that 1.3 million women experienced inti-
mate partner violence in 2015/2016 in the UK.3 Mean costs 
per abused woman were therefore £2043. We assumed 
that the costs of intimate partner abuse are similar to 
the costs of abuse by other family members, and that the 
costs would not differ between identified or unidentified 
abuse. In sensitivity analyses, we have allowed the costs of 
identified abuse to increase or decrease by 10% compared 
with abuse that was not identified; similarly, the costs of 
abused and identified, seeing advocate educator were allowed 
to increase or decrease by 25%.
Cost-utility analysis
Costs and utilities were applied to each health state. 
Total costs and QALYs for the hypothetical cohort were 
Parameter
Base 
case 
value
Lower 
limit
Upper 
limit Distribution Source
IRIS trial 
base 
value*
  Abused and identified, not seeing advocate 
educator
0.63 0.503 0.749 Beta 24 – 
Costs
  Costs of the intervention, per women registered, 
per 6 months
£0.46† £0.01 £1.69 Gamma IRIS-
programme 
local sites
£0.55
  Cost of onward referral, once £312† £8 £1127 Gamma IRIS-
programme 
local sites 
& 11
£298
  Cost of abused but not identified £2043 £52 £7536 Gamma 8 £4721
  Weighted costs abused and identified, seeing 
advocate educator
1 0.75 1.25 Gamma Assumption –
  Weighted costs abused and identified, not seeing 
advocate educator
1 0.9 1.1 Gamma Assumption – 
Costs are in 2015/2016 UK£.
*Values obtained from Devine et al.11
†Value updated from Devine et al.11
‡Internal calculation based on model calibration. 
Table 1 Continued 
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generated for the IRIS programme and the control 
group. The main outcome was the incremental costs 
per QALY gained. In the UK, an intervention is gener-
ally considered cost-effective when the incremental costs 
per QALY gained are <£20 000.14 We also presented the 
results of cost-effectiveness analysis in terms of incre-
mental net monetary benefit (NMB). This was calculated 
as the mean incremental QALYs per woman registered 
at the general practice accruing to IRIS multiplied by 
the decision-makers’ maximum willingness to pay for a 
QALY (assumed to be £20 000), minus the mean incre-
mental cost per woman. Negative incremental NMBs indi-
cate that usual care was preferred on cost-effectiveness 
grounds and positive incremental NMBs favour IRIS.
The cost-utility analysis was conducted using pooled 
national data, but we have also evaluated the cost-effec-
tiveness at different local sites. We allowed all parame-
ters, including costs and benefits, to vary across sites and 
reported them individually.
sensitivity analysis
All parameters were varied in a one-way sensitivity analysis, 
using lower and upper limits based on 95% uncertainty 
intervals. We undertook a probabilistic sensitivity analysis, 
drawing random samples from the probability distribu-
tions of all parameters in 1000 simulations. All uncertainty 
intervals were calculated based on the 2.5th and 97.5th 
percentiles of the distribution of all the 1000 values in 
the probabilistic sensitivity analysis. The interpretation of 
these is different to that of statistical analysis CIs of clin-
ical effects. In cost-effectiveness analysis, if an incremental 
cost-effectiveness ratio (ICER) has an uncertainty interval 
that crosses zero, it effectively means that the intervention 
can be cost-saving (negative value), cost-neutral (zero) or 
costly (positive value) per QALY gained. The proportion 
of simulations with an incremental cost per QALY gained 
below the cost-effectiveness threshold was calculated for 
different values, ranging from £0 to £50 000. The results 
were presented in a cost-effectiveness acceptability curve.
Patient and public involvement
We did not directly include patient and public involve-
ment (PPI) in this study, but the data collected from local 
IRIS programmes were developed with PPI.
results
base case
Parameter values used in the base case analysis are shown 
in table 1, which also includes the parameters used in the 
original trial to allow for a direct comparison. The main 
differences between the parameters for this study and the 
trial parameters lie in the transition probabilities relating 
to the health state of ‘abuse but not identified’ and its 
cost.
Over the 10-year time horizon, mean total costs per 
woman were £4416 in the intervention group, compared 
with £4430 in the control group (table 2(a)). The IRIS 
programme therefore saves £14 per woman aged 16 
years and older registered to GP practices, from a soci-
etal perspective over 10 years. Total QALYs per woman 
were 0.001 higher in the intervention group (6.671) than 
in the control group (6.669). Because the intervention 
was associated with lower costs and greater effectiveness, 
the incremental cost per QALY gained was negative (ie, 
IRIS dominates current practice as it is both cost-saving 
and more effective than usual care) and the incremental 
NMB was positive (£42). The incremental NMB was 
also positive (£22) when using an NHS-only perspective 
(table 2(b)).
Table 2 also presents the results for each site. The table 
shows that IRIS dominated current practice, from a soci-
etal perspective, in sites 1, 2, 3 and 4, with an incremental 
NMB of £41, £89, £29 and £59, respectively. From an NHS 
perspective, only in site 1 did IRIS dominate current prac-
tice, although it was cost-effective, using the threshold 
advised by the National Institute for Health and Care 
Excellence (NICE) of £20 000 per QALY gained, in sites 2 
(ICER £2585 per QALY gained), 3 (ICER £3055 per QALY 
gained) and 4 (ICER £8317 per QALY gained). IRIS was 
found to be cost-effective (ICER £5882 per QALY gained) 
and borderline cost-effective (ICER £21 229 per QALY 
gained) from a societal and NHS perspectives, respec-
tively in site 5, and it was not cost-effective from either 
perspective in site 6 (ICER £52 557 per QALY gained and 
ICER £64 427 per QALY gained, respectively).
sensitivity analyses
Across all sites combined, results were most sensitive to 
varying the transition probability from abused but not iden-
tified to not abused. When in the control arm this was varied 
from 0.049 to 0.051, the incremental NMB varied from 
£110 to −£26 (figure 2). When it was varied similarly in 
the intervention arm, the incremental NMB varied from 
−£25 to £109. Figure 2 shows the 12 parameters that when 
varied had the highest impact on the incremental NMB.
Incremental costs and QALYs varied widely in proba-
bilistic sensitivity analyses. The 95% uncertainty interval 
for incremental costs was −£151 to £37, for incremental 
QALYs it was −0.005 to 0.006 and for the incremental 
NMB it was −£247 to £351. Figure 3A shows a scatter plot 
of the incremental costs and incremental QALYs from 
the 1000 simulations. The IRIS programme is cheaper 
and more effective than the absence of the programme 
(usual care), dominating current practice in 35% of 
the simulations and was dominated by the absence of 
the programme in 18% of the simulations. The IRIS 
programme was cost-effective in 61% of simulations when 
the cost-effectiveness threshold was £20 000 (figure 3B).
DIsCussIOn
summary
We found that the IRIS GP training and service 
programme is likely to be cost-effective and cost-saving 
in the UK compared with usual care. The QALY gains 
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associated with IRIS, which are average values for all 
eligible women aged 16 years or over registered at a prac-
tice (and not, eg, those who have been abused), are small; 
these are balanced against an equally small incremental 
cost of the intervention. Interventions with small costs 
and small gains are not uncommon in public health: a 
Table 2 Base case results
National IRIS (pooled results)
(a) Societal perspective (b) NHS-only perspective
Costs QALYs Cost-effectiveness Costs QALYs Cost-effectiveness
Intervention (IRIS programme) £4416 6.671 £1238 6. 671
Control (no programme) £4430 6.669 £1232 6. 669
Difference (intervention vs control) −£14 0.001
−ve (intervention 
dominates control) £6 0.001
£3913 per QALY 
gained
Incremental NMB* £42 £22
Local site 1
  Intervention (IRIS programme) £4318 6.671 £1231 6.671
  Control (no programme) £4334 6.669 £1232 6.669
  Difference (intervention vs control) −£16 0.001
−ve (intervention 
dominates control) −£1 0.001
−ve (intervention 
dominates control)
  Incremental NMB* £41 £26
Local site 2
  Intervention (IRIS programme) £4305 6.673 £1240 6.673
  Control (no programme) £4333 6.670 £1232 6.670
  Difference (intervention vs control) −£28 0.003
−ve (intervention 
dominates control) £8 0.003
£2585 per QALY 
gained
  Incremental NMB* £89 £54
Local site 3
  Intervention (IRIS programme) £4325 6.671 £1235 6.671
  Control (no programme) £4334 6.670 £1232 6.670
  Difference (intervention vs control) −£9 0.001
−ve (intervention 
dominates control) £3 0.001
£3055 per QALY 
gained
  Incremental NMB* £29 £17
Local site 4
  Intervention (IRIS programme) £4326 6.672 £1253 6.672
  Control (no programme) £4334 6.669 £1232 6.669
  Difference (intervention vs control) −£8 0.003
−ve (intervention 
dominates control) £21 0.003
£8317 per QALY 
gained
  Incremental NMB* £59 £30
Local site 5
  Intervention (IRIS programme) £4337 6.670 £1244 6.670
  Control (no programme) £4332 6.669 £1232 6.669
  Difference (intervention vs control) £4 0.001
£5882 per QALY 
gained £12 0.001
£21 229 per QALY 
gained
  Incremental NMB* £6 £0
Local site 6
  Intervention (IRIS programme) £4395 6.671 £1307 6.671
  Control (no programme) £4334 6.670 £1232 6.670
  Difference (intervention vs control) £61 0.001
£52 557 per QALY 
gained £75 0.001
£64 427 per QALY 
gained
  Incremental NMB* −£38 −£52
Costs are in 2015/2016 UK£. Numbers may not sum due to rounding. 
*Measured at a willingness to pay for a QALY of £20 000.
Costs are in 2015/2016 UK£. Numbers may not sum due to rounding.
IRIS, Identification and Referral to Improve Safety; NMB, net monetary benefit; QALY, quality-adjusted life- year. 
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well-known example is influenza vaccination.25 26 There is 
considerable uncertainty surrounding these results, but 
the probability that IRIS is cost-effective was >60% at the 
cost-effectiveness threshold commonly used in the UK. 
The cost-effectiveness acceptability curve is relatively flat, 
implying that the results from IRIS do not change much 
regardless of the threshold used. In our view, the shape 
of the cost-effectiveness analysis curve (CEAC) is entirely 
consistent with the 95% uncertainty intervals. The fact 
that these values are close to 50% reflects there is a high 
level of uncertainty, and the fact that the probability that 
IRIS is cost-effective is just >50% reflects the fact that 
IRIS is (slightly) favoured over the alternative according 
to our base case estimates. IRIS was more cost-effective 
when costs were measured from a societal perspective as 
the cost savings from reducing DVA were higher. IRIS was 
also cost-effective when taking an NHS-only perspective. 
There was some variation in value for money between 
sites, which appears to be driven mainly by the different 
rates of identification and/or referral, although different 
local costs have also contributed.
Comparison with existing literature
We contacted researchers in the field and searched 
the NHS Economic Evaluations Database and the HTA 
Database at the Centre for Reviews and Dissemination27 
for cost-effectiveness analyses of DVA programmes 
using the search terms ‘domestic violence’ and ‘cost*’ 
(28 August 2017). We identified four economic impact 
studies, all using modelling methods: one based on 
the pilot of the IRIS trial,22 another based on the main 
trial,11 the third based on an evaluation of independent 
domestic violence advisors28 and the fourth of a trial of 
cognitive trauma therapy for abused women who have 
left the abusive relationship.28 All the studies found the 
interventions cost-effective, despite uncertainty. Devine et 
al has reported a 75% probability of the DVA intervention 
being cost-effective,11 while Mallender et al reported two 
scenarios out of possible five in which the intervention is 
not cost-effective.28 Our findings are consistent with these 
previous studies. Our study is the only one that analyses 
the economic impact of a primary care-based programme 
implemented outside of trial settings.
strengths and limitations
Our analysis has the strength of being based on a previ-
ously published cost-effectiveness model, updated with 
real-life data. Importantly, intervention costs and the 
probability of referral with IRIS were based on actual 
clinical practice, rather than in a research setting. We 
Figure 2 Univariate sensitivity analysis. All analyses are as for the base case analysis with univariate adjustment of the 
parameters listed (see text). Results are point estimates of the incremental net monetary benefit (NMB) of the intervention vs 
control. The incremental NMB is calculated at a maximum willingness to pay for a quality-adjusted life-year of £20 000.
Figure 3 Probabilistic sensitivity analysis. (A) Scatter plot of incremental costs and incremental quality-adjusted life-years 
(QALYs) from 1000 simulations. (B) Cost-effectiveness acceptability curve showing the probability in percentage terms that the 
intervention is cost-effective vs control at different values of the maximum willingness to pay for a QALY. Costs are in 2015/2016 
UK£.
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also had new data for the probability of identifying abuse 
and for what happened to women who were abused in 
current practice without the programme. However, it was 
not possible to update all parameter values. In partic-
ular, we were unable to update the utility value estimates, 
although in the sensitivity analysis, we have allowed these 
to vary and results were relatively stable. Costs of the inter-
vention were calculated by dividing the total costs of the 
programme over all registered women in practices with the 
IRIS programme. Many of these women will never expe-
rience abuse and therefore cannot directly benefit from 
the programme. If programme costs were divided over 
women experiencing abuse only, mean costs per woman 
would be higher. However, the QALYs gained would also 
be higher, as these are also calculated for all women in 
the practices rather than just those who were abused. In 
fact, we have attempted to calculate these results dividing 
cost and QALYs over women experiencing abuse and the 
final ICER was unchanged, as both the numerator and 
denominator change by the same proportion. We did not 
include any impact of the IRIS programme on children 
exposed to DVA, as to our knowledge, there are no avail-
able cohort studies focusing on the costs and benefits of 
DVA interventions for this population, which might mean 
that we have underestimated the programme’s cost-effec-
tiveness. This was also highlighted in the NICE economic 
analysis of interventions to reduce incidence and harm 
of DVA: 'It can be expected there are likely to be addi-
tional benefits such as (to) the children and wider family 
members of victims of domestic violence' (p. 11).28
Another limitation is that we have used mainly data 
on short-term outcomes, although modelled long-term 
outcomes. There is unfortunately little data on long-term 
outcomes of DVA and the effect of advocacy, although it 
is generally agreed that effects last for a long time. This, 
however, bias our estimates against the intervention, 
implying our results are conservative.
Implications for research and/or practice
The IRIS programme is likely to be cost-effective and 
cost-saving when implemented in the real life in the 
UK NHS. In order to decrease uncertainty around the 
cost-effectiveness estimates of IRIS and programmes 
like it, more data are needed on the utilities of women 
identified and women seeing an advocate and on long-
term outcomes associated with DVA. Furthermore, future 
research should endeavour to understand the impacts 
and economic burden of DVA on exposed children, other 
family members and friends as well as focus on collecting 
up-to-date utility values for women subject to DVA in each 
health state.
Finally, our study has shown that there is moderate vari-
ation in the value for money of IRIS across different sites, 
implying qualitative research could focus on identifying 
the causes of such variation, in order to reduce it.
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